Our Heritage - 
University of Oxford

Excellence in Neuropathology, Neuroimaging and the Healthcare sector.

Worldwide there are an estimated 50 million dementia sufferers, with 10 million new cases annually. Dementia has been the leading cause of death in England and Wales since 2015 and is a growing burden on economies around the world with the number of people suffering from dementia increasing every year – expected to reach 75 million in 2030 and 131 million in 2050.


Oxford Brain Diagnostics (OBD) has a novel and patented approach, called Cortical Disarray Measurement (CDM), as the result of an 8-year collaboration between Dr. Steven Chance (Neuroscience and Pathology) and Prof. Mark Jenkinson (Neuroimaging) at the University of Oxford. Our technology can identify and then measure the progression of the disease and how it responds to treatment by examining changes in the microscopic brain structure extracted from MRI scan data. 


Through this world leading research, we are bringing to market an early diagnosis tool for Alzheimer’s Disease, with the potential to be used to identify other brain conditions as the company grows and expands into new markets.  Our global excellence in the commercialisation of research was recently recognized by Nature Research, earning us a place as a finalist for their Spinoff Prize. 

Follow us on Linkedin and Twitter.  Make a difference in the world of neurological disorders. 

Oxford Brain Diagnostics Ltd is a company registered in England and Wales. Registered No. 11703979 

Oxford Centre for Innovation, New Road, Oxford, OX1 1BY

VAT No. 321 3026 62